<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-EYXJH2IV</identifier><date>2012</date><creator>Bojnec, Štefan</creator><creator>Kajdiž, Romana</creator><relation>documents/doc/E/URN_NBN_SI_doc-EYXJH2IV_001.htm</relation><relation>documents/doc/E/URN_NBN_SI_doc-EYXJH2IV_001.pdf</relation><relation>documents/doc/E/URN_NBN_SI_doc-EYXJH2IV_001.txt</relation><format format_type="volume">81</format><format format_type="issue">9</format><format format_type="type">article</format><format format_type="extent">str. 618-625</format><identifier identifier_type="COBISSID">1024467540</identifier><identifier identifier_type="ISSN">1318-0347</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-EYXJH2IV</identifier><language>slv</language><publisher>Slovensko zdravniško društvo</publisher><source>Zdravniški vestnik</source><rights>BY-NC</rights><subject language_type_id="slv">cene zdravil</subject><subject language_type_id="slv">določanje cen medsebojno zamenljivih zdravil z najvišjo priznano vrednostjo</subject><subject language_type_id="slv">eksterne referenčne cene</subject><subject language_type_id="eng">external reference price</subject><subject language_type_id="eng">internal reference prices</subject><subject language_type_id="slv">interne referenčne cene</subject><subject language_type_id="slv">kritje cen zdravil</subject><subject language_type_id="eng">price regulation for medicinal products</subject><subject language_type_id="eng">prices of medicinal products</subject><subject language_type_id="eng">reference pricing mutually interchangeable medicinal products with maximum attributed value</subject><subject language_type_id="slv">regulacija cen zdravil</subject><subject language_type_id="eng">reimbursement of expenses for medicinal products</subject><subject language_type_id="eng">Slovenia</subject><subject language_type_id="eng">Sloveniaj</subject><subject language_type_id="slv">Slovenija</subject><title>Ali regulacija in kritje cen zdravil vplivata na javne izdatke za zdravila?</title><title>Do the price regulation and reimbursement affect public expenditures for medicinal products?</title></Record>